SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Zealand Pharma A/S (ZEAL) .
本页证实的标准:
- VALUE (100/100, 通过) — 分析师目标价暗示上行空间 (+64.9%).
- 分析师共识目标价 $29.00 (+64.9% 上行空间) — 华尔街分析师认为存在显著上行潜力。
SharesGrow 综合评分： 56/100 其中 2/7 项标准通过。
SharesGrow 7-Criteria Score
✓
价值
100/100
Price-to-Earnings & upside
Proven by this page
~
健康
50/100
Debt-to-Equity & liquidity
→ Health
估值概览 — ZEAL
估值倍数
P/E (TTM)0.0
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率2.31
EV/EBITDA0.0
每股数据
EPS (TTM)$-26.54
每股账面价值$0.00
每股营收$7.62
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
股息收益率0.00%
分析师目标价$29.00 (+64.9%)
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2012 |
$1.60 |
$223.57M |
$36.37M |
16.3% |
| 2013 |
$-8.12 |
$6.57M |
$-183.68M |
-2794% |
| 2014 |
$-2.87 |
$153.77M |
$-64.99M |
-42.3% |
| 2015 |
$-4.82 |
$187.68M |
$-113.96M |
-60.7% |
| 2016 |
$-6.33 |
$234.78M |
$-153.91M |
-65.6% |
| 2017 |
$-9.77 |
$139.78M |
$-272.27M |
-194.8% |
| 2018 |
$18.94 |
$37.98M |
$581.28M |
1530.6% |
| 2019 |
$-16.91 |
$41.33M |
$-571.54M |
-1382.8% |
| 2020 |
$-22.07 |
$353.31M |
$-846.73M |
-239.7% |
| 2021 |
$-26.54 |
$292.57M |
$-1.02B |
-348% |
